Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 7;12(1):e12135.
doi: 10.1002/dad2.12135. eCollection 2020.

Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges

Affiliations
Free PMC article

Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges

Maura Bellio et al. Alzheimers Dement (Amst). .
Free PMC article

Abstract

Recent data-sharing initiatives of clinical and preclinical Alzheimer's disease (AD) have led to a growing number of non-clinical researchers analyzing these datasets using modern data-driven computational methods. Cognitive tests are key components of such datasets, representing the principal clinical tool to establish phenotypes and monitor symptomatic progression. Despite the potential of computational analyses in complementing the clinical understanding of AD, the characteristics and multifactorial nature of cognitive tests are often unfamiliar to computational researchers and other non-specialist audiences. This perspective paper outlines core features, idiosyncrasies, and applications of cognitive test data. We report tests commonly featured in data-sharing initiatives, highlight key considerations in their selection and analysis, and provide suggestions to avoid risks of misinterpretation. Ultimately, the greater transparency of cognitive measures will maximize insights offered in AD, particularly regarding understanding the extent and basis of AD phenotypic heterogeneity.

Keywords: Alzheimer's disease; cognition; cognitive tests; composite scores; data‐driven computational models; data‐sharing initiatives; mild cognitive impairment; predictive models.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart representing example (A) research questions and steps regarding (B) test selection, (C) quality control and standardization, and (D) computational/statistical methods. Example research questions (A) correspond closely to test selection (B), while subsequent processes outlined in steps C and D are broadly relevant across questions and tests. Example measures are reported in italics and section headings underlined. Dashed arrows indicate revisiting steps, for example, revisiting test selection owing to missing data

Similar articles

Cited by

  • A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias.
    Shaaban CE, Tudorascu DL, Glymour MM, Cohen AD, Thurston RC, Snyder HM, Hohman TJ, Mukherjee S, Yu L, Snitz BE. Shaaban CE, et al. Front Neuroimaging. 2022;1:978350. doi: 10.3389/fnimg.2022.978350. Epub 2022 Sep 26. Front Neuroimaging. 2022. PMID: 37464990 Free PMC article.
  • Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.
    de Erausquin GA, Snyder H, Brugha TS, Seshadri S, Carrillo M, Sagar R, Huang Y, Newton C, Tartaglia C, Teunissen C, Håkanson K, Akinyemi R, Prasad K, D'Avossa G, Gonzalez-Aleman G, Hosseini A, Vavougios GD, Sachdev P, Bankart J, Mors NPO, Lipton R, Katz M, Fox PT, Katshu MZ, Iyengar MS, Weinstein G, Sohrabi HR, Jenkins R, Stein DJ, Hugon J, Mavreas V, Blangero J, Cruchaga C, Krishna M, Wadoo O, Becerra R, Zwir I, Longstreth WT, Kroenenberg G, Edison P, Mukaetova-Ladinska E, Staufenberg E, Figueredo-Aguiar M, Yécora A, Vaca F, Zamponi HP, Re VL, Majid A, Sundarakumar J, Gonzalez HM, Geerlings MI, Skoog I, Salmoiraghi A, Boneschi FM, Patel VN, Santos JM, Arroyo GR, Moreno AC, Felix P, Gallo C, Arai H, Yamada M, Iwatsubo T, Sharma M, Chakraborty N, Ferreccio C, Akena D, Brayne C, Maestre G, Blangero SW, Brusco LI, Siddarth P, Hughes TM, Zuñiga AR, Kambeitz J, Laza AR, Allen N, Panos S, Merrill D, Ibáñez A, Tsuang D, Valishvili N, Shrestha S, Wang S, Padma V, Anstey KJ, Ravindrdanath V, Blennow K, Mullins P, Łojek E, Pria A, Mosley TH, Gowland P, Girard TD, Bowtell R, Vahidy FS. de Erausquin GA, et al. Alzheimers Dement (N Y). 2022 Sep 22;8(1):e12348. doi: 10.1002/trc2.12348. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36185993 Free PMC article.
  • Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.
    Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, Toledo JB, Ferreira D, Urwyler P, Weil RS, Kane J, Pilotto A, Rongve A, Boeve B, Taylor JP, McKeith I, Aarsland D, Lewis SJG; Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area - Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)+. Rodriguez-Porcel F, et al. Transl Neurodegener. 2022 May 2;11(1):24. doi: 10.1186/s40035-022-00299-w. Transl Neurodegener. 2022. PMID: 35491418 Free PMC article. Review.

References

    1. Young AL, Oxtoby NP, Daga P, et al. A data‐driven model of biomarker changes in sporadic Alzheimer's disease. Brain. 2014;137(Pt 9):256‐2577. - PMC - PubMed
    1. Crane PK, Trittschuh E, Mukherjee S, et al. Incidence of cognitively defined late‐onset Alzheimer's dementia subgroups from a prospective cohort study. Alzheimer's Dement. 2017;13(12):1307‐1316. - PMC - PubMed
    1. Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain imaging and behavior. 2012;6(4):517–527. - PMC - PubMed
    1. Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimer's Dement. 2017;13(8):870‐884. - PMC - PubMed
    1. Schneider LS, Goldberg TE. Composite cognitive and functional measures for early stage Alzheimer's disease trials. Assess Dis Monit. 2020;12(1).1–9. - PMC - PubMed